Gastrointestinal Tumors

Focus on

Genetics in GI Cancer
The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor. Targeting specific molecular pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy, recognizing and dealing with side effects and, importantly, the development of resistance.

This book provides an up-to-date overview of the advances and limitations of targeted therapy for several tumor entities including breast cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, melanoma, ovarian cancer and renal cell carcinoma. Written by over a dozen internationally renowned scientists, the book is suitable for advanced students, postdoctoral researchers, scientists and clinicians who wish to update their knowledge of the latest approaches to targeted cancer therapies.
Guidelines for Authors

Aims and Scope
Gastrointestinal Tumors is an international, peer-reviewed journal that brings together the leading opinions in all fields related to gastrointestinal cancer research. Ranging from the identification of new therapeutic targets to epidemiology, disease prevention, treatment and patient management, the journal provides a platform for the dissemination of key opinions from thought leaders in the field. By publishing timely reviews covering the latest developments, the journal will help readers gain insight into the evolving body of research across the relevant disciplines.

Submission
The Journal accepts Invited Review Articles which provide expert overviews of recent key data and therapeutic regimens. An Abstract is required and should be divided into Background, Summary, Key Message and Practical Implications. Manuscripts should be submitted to:

Editorial Office ‘Gastrointestinal Tumors’
S. Karger AG
Ms. Ricardo Cueni
PO Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1343
Fax +41 61 306 1234
E-Mail t.cueni@karger.com

All manuscripts must be accompanied by a cover letter and copyright signed by all authors. Assurance should be given in the cover letter that the manuscript is not under simultaneous consideration by any other publication.

Invited Review Articles provide expert overviews of the latest clinical data and therapeutic regimens.

The privileged nature of these articles is reflected by their publication under these special conditions:
- No publication charges
- Reviewed using a fast track peer-review process
- Free PDF article file for the author after publication
- Published online in free access mode (full text special conditions: is reflected by their publication under these

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance to rework it. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Arrangement
The manuscript should conform to the following order: title page, abstract and key words, body, acknowledgments, references, figure legends, tables and figures. Manuscripts should be written in high-quality English suitable for effective communication to a professional medical audience. For authors whose native language is not English, use of a professional language editing service (http://www.karger.com/Resource/Authors) prior to submission can help to avoid delays with the review process. All pages, including the figure legends, should be numbered in sequence, and the first author's name should be at the upper right corner of each page. Papers not conforming to the journal style will be returned without review.

Title page: The first page of each paper should indicate a concise title of no more than 150 characters, all authors' names (first name and surname), authors' institutional affiliations, and a short title for use as running head. Corresponding author: The exact postal address of the corresponding author (corresponding author is indicated with an *). The corresponding author's name should appear at the upper right corner of each page. Papers not conforming to the journal style will be returned without review.

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Gastrointestinal Tumors and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Disclosures
Authors are required to disclose any potential or funding arrangements relating to their research. All authors should disclose any possible conflicts of interest. Disclosure statements will be published at the end of the text of the article.

Ethics
Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institution's committee on human research. Further, they should also state that animal experiments conform to institutional standards. Authors are required to declare the approval codes obtained from the corresponding ethical committee on human and/or animal research.

References
In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. List of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Theocharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Author's Choice™
Karger's Author's Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at
Guidelines for Authors

www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the review article. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

- Be used for non-commercial purposes only
- Be linked to the final version on www.karger.com
- Include the following statement:

  ‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article. Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author’s Choice™ (Gold Open Access) articles, see Author’s Choice™.

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

- Follow the terms of the relevant Creative Commons license
- Be linked to the final version on www.karger.com
- Include the following statement:

  ‘The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
General Information

ISSN Print Edition: 2296–3774
ISSN Online Edition: 2296–3766

Journal Homepage: www.karger.com/gat

Publication Data: Gastrointestinal Tumors is published 4 times a year. Volume 2 with 4 issues appears in 2015.

Copyright © 2015 S. Karger AG, Basel (Switzerland). All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.

Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Subscription Rates: Subscriptions run for a full calendar year. Prices are given per year.

Personal subscription:

Print or Online
CHF 260.00
EUR 217.00
USD 265.00

Print+Online combined
CHF 308.00
EUR 256.00
USD 313.00

Postage and handling (added to print and print+online)
CHF 30.40 Europe, CHF 44.80 Overseas
EUR 25.60
USD 41.60

Institutional subscription:

Print or Online
CHF 1545.00
EUR 1288.00
USD 1577.00

Print+Online combined
CHF 1777.00
EUR 1481.00
USD 1814.00

Postage and handling (added to print and print+online)
CHF 38.00 Europe, CHF 56.00 Overseas
EUR 32.00
USD 52.00

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.com.

Bibliographic Indices: This journal is regularly listed in bibliographic services.

Photocopying: This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to Copyright Clearance Center Inc.

A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger AG, PO. Box CH–4009 Basel (Switzerland).

Guidelines for Authors

www.karger.com/gat_guidelines

Downloaded by: 54.70.40.11 - 10/21/2017 7:15:08 PM
Contents

See the journal website for contents
29 JUNE - 2 JULY 2016
BARCELONA, SPAIN

Chairs
Mario Dicato, MD
Luxembourg Medical Center
Luxembourg, Luxembourg

Eric Van Cutsem, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Vice Chair
Josep Tabernero, MD, PhD
Vall d’Hebron University Hospital
Barcelona, Spain

REGISTER ONLINE AT WORLDGICANCER.COM

IMPORTANT DATES
Early Registration Deadline 7 April 2016
Discounted Registration Deadline 16 June 2016
Abstract Submission Deadline 7 March 2016
Therapy of Hepatitis B Virus Infections – Potential and Limitations

Editors
W.H. Gerlich
D. Glebe
L.G. Gürtler
R. Kaiser

Although the beginnings of hepatitis B therapy date back to 1976, it has only been in the last 10 years that it has gradually reached a satisfactory level of efficacy and dependency. According to the latest studies, many cases of chronic hepatitis B may need life-long therapy while others may reach, after several years, a kind of cure mediated by the host immune system. The main purpose of hepatitis B virus therapy is the prevention of the life-threatening late complications like liver cirrhosis and hepatocellular carcinoma, but it is also increasingly gaining a place in severe acute hepatitis and in the prevention of reactivation or transmission of the infection in various settings. This special issue of Intervirology contains contributions from internationally renowned virologists and hepatologists who describe these additional applications. Furthermore, the remaining problems and the latest approaches to overcome them are discussed. Primarily addressing clinical virologists and hepatologists, this publication is also relevant for those who are interested in therapy and prevention of infectious diseases, including public health specialists.

Contents
Preface

Background on Hepatitis B Virus
• Molecular Virology of Hepatitis B Virus and Targets for Antiviral Intervention: Glebe, D.; König, A.
• Genotypes and Genetic Variability of Hepatitis B Virus: Kramvis, A.

Therapeutic Targets
• Inhibitors of Hepatitis B Virus Attachment and Entry: Lempp, F.A.; Urban, S.
• Host Factor-Targeted Hepatitis B Virus Therapies: Gehring, A.; Bertoletti, A.; Tavis, J.E.

Clinical Applications
• Therapy of Hepatitis B Virus Infections: Potential and Limitations: Brunetto, M.R.; Bonino, F.
• Antiviral Therapy of Chronic Hepatitis B: van Bommel, F.
• Therapy of Acute and Fulminant Hepatitis B: Tillmann, H.L.; Patel, K.
• Therapy of Occult Hepatitis B Virus Infection and Prevention of Reactivation: Raimondo, G.; Filomia, R.; Maimone, S.
• Prevention of Hepatitis B Virus Reinfection in Liver Transplant Recipients: Roche, B.; Samuel, D.
• Reduction of Infectivity in Chronic Hepatitis B Virus Carriers among Healthcare Providers and Pregnant Women by Antiviral Therapy: Gerlich, W.H.
• Effect of Antiretroviral HIV Therapy on Hepatitis B Virus Replication and Pathogenicity: Gürtler, L.G.

Resistance
• Mechanisms of Hepatitis B Virus Resistance Development: Warner, N.; Locarnini, S.
• Selected Phenotypic Assays Used to Evaluate Antiviral Resistance and Viral Fitness of Hepatitis B Virus and Its Variants: Glebe, D.; Geipel, A.
• Hepatitis B Virus Drug Resistance Tools: One Sequence, Two Predictions: Neumann-Fraune, M.; Beggel, B.; Kaiser, R.; Obermeier, M.

Karger – Medical and Scientific Publishers
CH–4009 Basel, Switzerland
orders@karger.com, f: +41 61 306 12 34
www.karger.com
Challenges in Inflammatory, Preneoplastic and Neoplastic Diseases of the Digestive System

Editor
Peter Malfertheiner

Contents

Review Articles

- Preneoplastic Conditions in the Stomach: Always a Point of No Return? Venerito, M.; Malfertheiner, P.
- Management of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: Neumeister, P.; Troppan, K.; Raderer, M.
- How Can Screening Colonoscopy Be Optimized? Waldmann, E.; Regula, J.; Fertlitsch, M.
- Serrated and Non-Serrated Precursor Lesions of Colorectal Cancer: Langner, C.
- Small Colorectal Polyps: Schoefl, R.; Ziachehabi, A.; Wewalka, F.
- Small Bowel Crohn’s Disease: An Emerging Disease Phenotype? Hall, B.; Holleran, G.; McNamara, D.
- Colorectal Cancer in Patients with Inflammatory Bowel Disease: The True Impact of the Risk: Herszényi, L.; Barabás, L.; Miheller, P.; Tulassay, Z.
- Chemoprevention of Colorectal Cancer: Lang, M.; Gasche, C.
- Risk Assessment in Early Colorectal Cancer: Histological and Molecular Markers: Resch, A.; Langner, C.
This interdisciplinary journal is unique in its field as it covers the principles of both gastrointestinal medicine and surgery required for treating abdominal diseases. In each issue invited reviews provide a comprehensive overview of one selected topic. Thus, a sound background of the state of the art in clinical practice and research is provided. A panel of specialists in gastroenterology, surgery, radiology, and pathology discusses different approaches to diagnosis and treatment of the topic covered in the respective issue. Original articles, case reports, and commentaries make for further interesting reading.

The journal is a valuable source of information, imparting essential knowledge for mastering the major interdisciplinary challenges in gastrointestinal medicine and surgery.
Editorial
Zhu, X.-Q.; Chen, H.-Y. (Shanghai)

Mini-Reviews

Genetic Variations and Gastric Cancer
Yu, C.-Y.; Chen, H.-Y. (Shanghai)

Hereditary Colorectal Cancer in China: Current Status and Progress
Li, C.-G. (Beijing/Chongqing); Yang, L.; Sheng, J.-Q. (Beijing)

Genetic Variations in Esophageal Cancer
Qian, J.; Fang, J.-Y. (Shanghai)

The Emerging Genetic Basis and Its Clinical Implication in Pancreatic Cancer
Chen, F.; Guo, Y.; Wang, L. (Hangzhou)

Original Papers

SIRT1 Is Reduced in Gastric Adenocarcinoma and Acts as a Potential Tumor Suppressor in Gastric Cancer
Zhang, Y.; Cai, X.; Chai, N.; Gu, Y.; Zhang, S.; Ding, M.; Cao, H.; Sha, S.; Yin, J.; Li, M.; Wu, K.; Nie, Y. (Xi'an)

p21 Gene Expression Evaluation in Esophageal Cancer Patients
Salari Fanoodi, T.; Motalleb, G. (Zabol); Yegane Moghadam, A.; Talaee, R. (Kashan)